Transaction details and context
On January 30, 2026, Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NASDAQ: NRIX), completed two distinct equity transactions tied to the company’s incentive plans. Hansen sold a total of 4,895 shares of common stock in two transactions that were executed to satisfy tax-withholding obligations arising from the award of equity. The per-share sales prices ranged from $16.5826 to $17.3717, producing gross proceeds of approximately $81,249.
That same day, Hansen also took delivery of 11,816 shares through the exercise of restricted stock units. The conversion of those restricted stock units occurred at a $0 exercise price. Following the net effect of those movements, Hansen now directly holds 83,672 shares of Nurix common stock.
Market positioning and price performance
Nurix is currently valued at about $1.7 billion and has experienced a notable share-price run-up, climbing 46.71% over the last six months despite persistent volatility. InvestingPro data cited in the company’s profile shows analysts collectively issuing a Strong Buy consensus, with explicit price target ranges stretching from $22 to $41.
InvestingPro’s analysis additionally flags a relatively high beta of 1.94 for the stock, indicating pronounced sensitivity to market moves. The platform notes that the shares are trading near what it defines as Fair Value and that a more comprehensive Pro Research Report on Nurix is available alongside coverage of more than 1,400 U.S. equities.
Recent analyst adjustments and company performance metrics
Several firms have recently revised price targets and reiterated positive stances in light of Nurix’s financial results and program updates. The company reported a net loss of $0.82 per share for the fourth quarter of fiscal 2025, a figure that marginally outperformed H.C. Wainwright’s expectation of a $0.84 per-share loss. After that release, H.C. Wainwright raised its price target to $32 and kept a Buy rating on the stock.
Piper Sandler raised its target to $35, noting the company’s accelerated development plans for its bexobrutideg program in chronic lymphocytic leukemia and small lymphocytic lymphoma. Stifel and BTIG remained positive as well, with Stifel assigning a $35 target and BTIG reiterating a $30 target while pointing to advancements in key programs and what it described as a strong cash position. RBC Capital also increased its target to $30, noting that recent updates — including ASH data and study design amendments — had already been disseminated to the market.
Collectively, these analyst moves reflect a broad and continuing optimism about the trajectory of Nurix’s development pipeline and its financial footing, as reported by the covered firms.
Investor takeaway
The insider transactions by Hansen were procedural in nature: shares were sold to cover tax liabilities tied to equity awards while a separate RSU conversion increased her share count at no cash outlay. Market participants will note the juxtaposition of sustained analyst endorsement and elevated price volatility, which bears on both short-term trading dynamics and longer-term investment assessments.